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Background. Chronic treatment with renin-angiotensin system (RAS) antagonists frequently
causes deleterious hypotension during anaesthesia. We compared the effects of angiotensin II
receptor antagonists (ARA) and angiotensin-converting enzyme inhibitors (ACEI) on neuro-
hormonal levels and haemodynamics during cardiopulmonary bypass (CPB).
Methods. Forty-four patients undergoing mitral valvular surgery who were treated with either
ARA (ARA group, n=14) or ACEI (ACEI group, n=15) over 12 weeks or who were not treated
with any RAS antagonist (control group, n=15) were enrolled. The plasma levels of epinephrine,
norepinephrine, arginine vasopressin (AVP) and angiotensin II, and haemodynamic variables were
measured before (T1) and 15 min after (T2) the start of CPB, before aortic unclamping (T3) and
at skin closure (T4). Mean arterial pressure (MAP) was maintained above 60 mm Hg with
phenylephrine administration during CPB.
Results. The plasma epinephrine, norepinephrine, AVP and angiotensin II levels increased during
CPB in all groups. Compared with the control group, the AVP level was lower at T1 in the ARA
group and at T2 in the ARA and ACEI groups. The angiotensin II level was higher at T1, T2 and T3
in ARA group compared with ACEI and control groups. There were no significant differences in
the epinephrine and norepinephrine levels among the three groups. The amount of administered
phenylephrine during CPB was greater and MAP was lower in the ARA group compared with the
ACEI and control groups.
Conclusions. Chronic ARA treatment resulted in more profound hypotension than ACEI
treatment during CPB, and this may be associated with the blockade of angiotensin II receptors
by ARA.
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Renin-angiotensin system (RAS) antagonists, such as
angiotensin II receptor antagonists (ARA) and angiotensin-
converting enzyme inhibitors (ACEI) have been increas-
ingly used in hypertension, heart failure and even in the
early stage of heart disease with reports of reduced mortality
and morbidity.1 2 However, long-term RAS inhibition with
ARA and ACEI disable the RAS to compensate for reduced
sympathetic tone, which can result in severe hypotension
during anaesthesia.3 Hypotensive episodes after the
induction of anaesthesia have been known to occur more
frequently in patients treated with ARA than in patients
treated with ACEI.4
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Cardiopulmonary bypass (CPB) frequently causes hypo-
tension as a result of tissue hypoxia and hypoperfusion,
haemodilution and systemic inflammatory response.5–8 It
is usually transient and mild because of subsequent tempor-
ary elevation in several vasoconstrictive substances,9 10 and
temporary administration of low dose of vasopressor is
usually sufficient to maintain perfusion pressure. However,
deleterious vasodilatory shock may develop during CPB,
requiring large amounts of vasopressors, which may be
associated with difficulty in weaning from CPB and poor
prognosis. Chronic treatment with ACEI is a known risk
factor for vasodilatory shock associated with CPB.11 12
The aim of this study was to investigate the effects of
long-term ARA and ACEI medications on vasoactive
neurohormonal levels, such as epinephrine, norepinephrine,
arginine vasopressin (AVP) and angiotensin II, and their
haemodynamic consequences in patients undergoing CPB.
Methods
Patients
After obtaining the approval of the institutional review
board and informed consent, 44 patients undergoing elective
mitral valvular surgery between September 2004 and
October 2005 were enrolled. The patients consisted of three
groups; patients who had been treated with either ARA
(ARA group, n=14) or ACEI (ACEI group, n=15) over
12 weeks, and patients who had not been treated with
any RAS antagonists (control group, n=15). All patients
had baseline systolic blood pressure below 130 mm Hg
on three consecutive days. Patients with left ventricular
ejection fraction <50%, New York Heart Association
(NYHA) functional class III or IV, on calcium channel
blocker medication, and/or with pre-existing endocrinal,
renal, hepatic, neurological or coronary artery occlusive
disease were excluded from this study.
Anaesthetic management
Cardiac medications were continued until the morning
of surgery and all patients were premedicated with
0.05 mg kg1 i.m. morphine 1 h before arriving in the
operating room. Five ECG leads were attached, and leads
II and V5 were continuously monitored. A 20-G radial artery
catheter was inserted under local anaesthesia. For continu-
ous cardiac output monitoring, thermodilutional pulmonary
artery catheter (Swan-Ganz, CCOmbo, Baxter Healthcare
Co., Irvine, CA, USA) was inserted via the right internal
jugular vein under local anaesthesia. After that, anaesthesia
was induced with midazolam 0.05 mg kg1, sufentanil
1.5 mg kg1 and rocuronium 50 mg, and maintained with
continuous infusion of sufentanil 0.5 mg kg1 h1, rocur-
onium 20–30 mg h1 and low dose of isoflurane (under
0.5 vol%) in oxygen (50%) with air during the surgery.
A transoesophageal echocardiographic probe was inserted
to monitor myocardial contractility and wall motion abnor-
mality. Arterial oxygen saturation, end-expiratory isoflurane
concentration (ET-Isof, vol%), nasopharyngeal and rectal
temperatures were monitored during the study. Mechanical
ventilation was controlled to maintain normocarbia
(4.7–5.0 kPa). The depth of anaesthesia was monitored
with a bispectral index score (BIS) monitor (A-200 BIS
monitor, Aspect Medical System Inc., Newton, MA,
USA) and maintained at 50 (5). Any mean arterial pressure
(MAP) below 60 mm Hg during the induction of anaesthesia
or during surgery, was treated by 100 mg of phenylephrine.
CPB was instituted with a membrane oxygenator
primed with 1.5 litre of crystalloid solution, and boluses
of sufentanil 1.5 mg kg1 and midazolam 0.05 mg kg1
were administered through the venous reservoir. Body
temperature was cooled to 32–33C. After aortic cross-
clamping, a hyperkalaemic cardioplegic solution was
administered through the aortic root and repeated at
30 min intervals. A non-pulsatile pump flow rate was main-
tained at 2.0–2.5 litre min1 m2. At the beginning of
rewarming, additional boluses of sufentanil 1.5 mg kg1
and midazolam 0.05 mg kg1 were administered. After
the completion of the surgical procedure and systemic
rewarming (rectal temperature of at least 35C), patients
were weaned from CPB. During CPB, MAP was maintained
above 60 mm Hg by the perfusionist who was blinded to the
patients study group assignment. When the MAP decreased
below 60 mm Hg during CPB, first the pump flow rate was
increased up to 3.0 litre min1 m2, thereafter phenyleph-
rine (100 mg ml1) was infused until MAP increased to
60 mm Hg.
Measurements and calculations
Haemodynamic variables including cardiac index (CI),
MAP, central venous pressure (CVP), heart rates (HR),
mean pulmonary arterial pressure (MPAP), and systemic
vascular resistance index (SVRI) were measured before
(T1, baseline) and 15 min after (T2) the start of CPB, before
aortic unclamping (T3) and at skin closure (T4). The number
of patients and the frequency requiring phenylephrine
bolus administration were recorded between induction
and before skin incision, between skin incision and before
CPB, and between termination of CPB and skin closure.
During CPB, the dose of infused phenylephrine was
recorded.
Arterial blood was sampled at T1, T2, T3 and T4 for
measuring plasma epinephrine, norepinephrine, AVP and
angiotensin II levels. Blood was collected in 5 ml poly-
propylene tube containing ethylenediaminetetraacetic acid
and centrifuged in a refrigerated centrifuge at 3000 g for
10 min to separate the plasma. The decanted plasma was
stored at 70C until analysis. Plasma epinephrine and
norepinephrine were measured by high-pressure liquid chro-
matography (SRL, Tokyo, Japan). Commercially available
radioimmunoassay kits were used to measure the plasma
ARA and ACEI during CPB
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AVP (Yuka AVP RIA, Mitsubishi Kagaku Medical, Tokyo,
Japan) and angiotensin II (angiotensin II kits, SRL) levels.
Statistical analysis
Data were analysed with SPSS (version 11.0, SPSS Inc.,
Chicago, IL, USA). Data were assessed for normal distri-
bution of variance with Kolmogorov–Smirnov test. Results
were expressed as number of patients or mean (SD). To
assess differences in patient characteristics among three
groups, one-way ANOVA with post hoc Tukey test and
x2-test or Fisher’s exact test were performed. To assess
differences in plasma neurohormonal levels, haemodynamic
variables, dose of administered phenylephrine during CPB
among three groups, one-way ANOVA with post hoc Tukey
test was performed. To assess differences in changes of
neurohormonal levels within each group, repeated-measures
ANOVA with respect to T1 was performed. To assess differ-
ences in the number of patients and the frequency requiring
phenylephrine administration between induction and before
skin incision, between skin incision and before CPB, and
between termination of CPB and skin closure among three
groups, x2-test or Fisher’s exact test were performed. A
P-value <0.05 was considered statistically significant.
Results
Patient characteristics
In the ARA group, candesartan (8 mg day1 in 2 pts,
16 mg day1 in 3 pts), losartan (25 mg day1 in 2 pts,
50 mg day1 in 3 pts), irbesartan (150 mg day1 in
2 pts) and valsartan (80 mg day1 in 2 pts) were taken.
In ACEI group, lisinopril (10 mg day1 in 3 pts, 20 mg
day1 in 3 pts), ramipril (2.5 mg day1 in 1 pt, 5 mg day1 in
4 pts) and cilazapril (1.25 mg day1 in 1 pt, 2.5 mg day1 in
3 pts) were taken. There were no differences in patient
characteristic data, types of mitral valvular disease, types
of operation, preoperative cardiac medications, preoperative
echocardiographic findings, duration of CPB and ACC
among three groups (Table 1).
Neurohormonal changes
Neurohormonal changes at each time point are presented in
Table 2. The plasma epinephrine level increased at T2 in the
control group and at T3 in the ARA and ACEI group com-
pared with values at T1 without between-group differences.
The plasma norepinephrine level increased at T2, T3 and T4
in all groups compared with values at T1 without between-
group differences.
The plasma AVP level in all groups increased at T2, T3
and T4 compared with values at T1. It was significantly
lower in the ARA group compared with that in the control
group at T1, and lower in the ARA and ACEI group com-
pared with that in the control group at T2. There was no
difference in the plasma AVP level between the ARA and
ACEI group.
The plasma angiotensin II level significantly increased at
T3 in all groups and at T4 in the control group compared
with values at T1. The plasma angiotensin II level was
significantly higher in the ARA group compared with
those in the ACEI and control group at T1, T2 and T3.
There was no difference in the plasma angiotensin II
level between the ACEI and control group.
Phenylephrine administration and haemodynamics
Between induction and before skin incision, and between
skin incision and before CPB, the number of patients and
Table 1 Patients characteristics. ACC, aortic cross-clamping; ACEI,
angiotensin-converting enzyme inhibitors; ARA, angiotensin II receptor antag-
onists; CPB, cardiopulmonary bypass; LA, left atrial; LV, left ventricular. Data
are presented as mean (range or SD) or number of patients. No significant
differences were seen among the three groups
Control
group
(n=15)
ACEI
group
(n=15)
ARA
group
(n=14)
Sex (male/female) 7/8 9/6 8/6
Age (yr) 59 (33–63) 55 (28–73) 60 (47–68)
Body surface area (m2) 1.63 (0.16) 1.69 (0.12) 1.60 (0.11)
Mitral valve lesion (n)
Regurgitation lesion 11 10 9
Stenotic lesion 5 5 5
Operation (n)
Mitral valve repair 8 6 6
Mitral valve replacement 7 9 8
Medication (n)
Digoxin 10 8 9
Diuretics 9 13 13
b-blockers 4 2 2
Echocardiography
LV ejection fraction (%) 59 (7) 62 (9) 59 (9)
LV diastolic dimension (mm) 54 (5) 58 (7) 56 (10)
LV systolic dimension (mm) 36 (3) 40 (7) 42 (8)
LA volume index (ml m2) 78 (40) 81 (23) 68 (32)
Intraoperative data
CPB time (min) 137 (25) 123 (29) 130 (26)
ACC time (min) 103 (27) 90 (14) 95 (25)
Table 2 Neurohormonal changes during CPB. ACEI, angiotensin-converting
enzyme inhibitors; ARA, angiotensin II receptor antagonists; AVP, arginine
vasopressin. T1, before the start of CPB; T2, 15 min after the start of CPB;
T3, before aortic unclamping; T4, skin closure. Data are presented as mean (SD).
*P<0.05 vs T1; †P<0.05 vs control group; ‡P<0.05 vs ACEI group
T1 T2 T3 T4
Epinephrine (ng ml1)
Control 0.04 (0.02) 0.10 (0.05)* 0.08 (0.03) 0.10 (0.07)
ACEI 0.05 (0.04) 0.06 (0.04) 0.21 (0.18)* 0.29 (0.26)
ARA 0.05 (0.03) 0.12 (0.09) 0.20 (0.17)* 0.18 (0.15)
Norepinephrine (ng ml1)
Control 0.19 (0.15) 0.82 (0.64)* 1.24 (0.88)* 1.11 (0.89)*
ACEI 0.36 (0.22) 1.25 (0.90)* 1.76 (1.24)* 1.72 (0.91)*
ARA 0.32 (0.18) 1.76 (1.03)* 2.47 (0.93)* 2.03 (0.54)*
AVP (pg ml1)
Control 19.6 (11.5) 109.7 (45.7)* 48.9 (32.4)* 36.7 (22.1)*
ACEI 11.9 (8.9) 49.0 (38.6)*† 29.2 (19.5)* 29.1 (13.7)*
ARA 7.0 (3.7)† 32.2 (17.4)*† 30.9 (18.0)* 25.7 (20.5)*
Angiotensin II (pg ml1)
Control 30.7 (20.3) 61.4 (49.8) 169.1 (140.3)* 141.0 (96.5)*
ACEI 30.3 (16.4) 76.5 (52.6) 193.0 (170.9)* 90.3 (86.4)
ARA 140.7 (98.2)†‡ 214.8 (149.7)†‡ 507.7 (299.8)*†‡ 185.3 (120.7)
Oh et al.
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the frequency requiring phenylephrine administration were
significantly higher in the ARA group than in the ACEI and
control group (Table 3). There were no significant differ-
ences between the ACEI and control group. Preoperative
haemodynamic variables were not different among the three
groups (Table 4). After the induction of anaesthesia, MAP
was significantly lower in the ARA group than in the control
group. Haemodynamic variables were not different among
the three groups at T1.
During CPB, all patients in the three groups required the
administration of phenylephrine. The dose of administered
phenylephrine was significantly greater in the ARA group
than in the ACEI and control group. MAP was lower in the
ARA group than in the control group at T2 and T3. SVRI
was lower in the ARA group than in the ACEI group at T2.
In conjunction with higher CI (pump flow), MAP and SVRI
were lower in the ARA and ACEI group than in the control
group at T3.
Table 3 Phenylephrine requirement during mitral valvular surgery. ACEI,
angiotensin-converting enzyme inhibitors; ARA, angiotensin II receptor antag-
onists; CPB, cardiopulmonary bypass. Data are presented as mean (SD) or num-
ber. *P<0.05 vs control group; †P<0.05 vs ACEI group. No significant
differences were seen between ACEI and control group
Control
group
(n=15)
ACEI
group
(n=15)
ARA
group
(n=14)
Between induction and before skin incision
No. of patients 2 4 10*†
Frequency 2 6 19*†
Between skin incision and before CPB
No. of patients 0 1 6*†
Frequency 0 2 8*†
During CPB
Total dose (mg) 3.3 (1.3) 5.1 (2.1) 10.7 (5.1)*†
Calculated infusion dose
(mg kg1 min1)
0.4 (0.2) 0.8 (0.4) 1.6 (0.9)*†
Between termination of CPB and skin closure
No. of patients 0 0 2
Frequency 0 0 2
Table 4 Haemodynamic variables during mitral valvular surgery. ACEI, angiotensin-converting enzyme inhibitors; ARA, angiotensin II receptor antagonists; BIS,
bispectral index score; CI, cardiac index; CVP, central venous pressure; ET-Isof, end-tidal isoflurane concentration; HR, heart rate; MAP, mean arterial pressure;
MPAP, mean pulmonary arterial pressure; NA, not applicable; RT, rectal temperature; SVRI, systemic vascular resistance index. T1, before the start of CPB; T2, 15
min after the start of CPB; T3, before aortic unclamping; T4, skin closure. Data are presented as mean (SD). *P<0.05 vs control group; †P<0.05 vs ACEI group
Pre-induction Post-induction T1 T2 T3 T4
MAP (mm Hg)
Control 91 (13) 82 (11) 86 (10) 71 (9) 75 (6) 81 (12)
ACEI 89 (12) 80 (9) 86 (14) 70 (9) 70 (9)* 81 (8)
ARA 85 (10) 73 (10)* 78 (7) 62 (5)* 70 (7)* 77 (7)
CI (litre min1 m2)
Control 2.9 (0.7) 2.8 (0.6) 2.7 (0.8) 2.6 (0.5) 2.5 (0.2) 2.8 (0.4)
ACEI 3.2 (1.1) 3.1 (0.7) 2.6 (1.0) 2.4 (0.4) 2.8 (0.3)* 2.9 (0.7)
ARA 2.7 (1.0) 2.7 (0.8) 2.5 (0.6) 2.8 (0.5) 2.9 (0.3)* 3.2 (0.6)
HR (beats min1)
Control 80 (23) 92 (21) 78 (15) NA NA 88 (16)
ACEI 84 (17) 84 (13) 81 (12) NA NA 88 (14)
ARA 81 (8) 80 (22) 82 (13) NA NA 96 (19)
MPAP (mm Hg)
Control 28.9 (9.0) 26.5 (12.0) 30.8 (8.4) NA NA 20.6 (3.2)
ACEI 21.7 (7.8) 20.9 (7.1) 26.3 (7.4) NA NA 19.6 (3.9)
ARA 23.4 (11.1) 22.3 (5.4) 25.9 (5.8) NA NA 19.7 (5.6)
CVP (mm Hg)
Control 7.6 (4.0) 7.3 (2.6) 8.6 (2.5) NA NA 9.5 (3.0)
ACEI 5.7 (2.7) 7.1 (2.6) 9.3 (2.1) NA NA 8.3 (2.9)
ARA 7.3 (1.6) 7.6 (1.3) 9.4 (2.7) NA NA 9.4 (3.0)
SVRI (dyn s cm5 m2)
Control 2480 (707) 2271 (717) 2501 (796) 2254 (587) 2340 (328) 2108 (584)
ACEI 2361 (1169) 2020 (545) 2724 (1157) 2417 (646) 1999 (364)* 2142 (712)
ARA 2595 (1064) 2130 (639) 2345 (493) 1774 (313)† 1935 (298)* 1696 (204)
Haematocrit (%)
Control 36 (4) 34 (4) 33 (3) 24 (3) 26 (4) 28 (3)
ACEI 37 (6) 36 (5) 35 (5) 24 (5) 26 (3) 29 (4)
ARA 37 (4) 35 (3) 33 (4) 23 (3) 24 (4) 27 (3)
RT (C)
Control NA NA 36.5 (0.4) 34.4 (0.7) 35.3 (0.7) 36.4 (0.3)
ACEI NA NA 36.3 (0.5) 34.4 (0.5) 35.1 (0.5) 36.5 (0.5)
ARA NA NA 36.4 (0.4) 34.3 (0.4) 35.1 (0.5) 36.3 (0.3)
ET-Isof (vol %)
Control NA 0.4 (0.2) 0.3 (0.2) 0.2 (0.1) 0.3 (0.1) 0.4 (0.1)
ACEI NA 0.3 (0.2) 0.3 (0.2) 0.2 (0.1) 0.3 (0.1) 0.4 (0.2)
ARA NA 0.3 (0.1) 0.3 (0.1) 0.2 (0.1) 0.3 (0.1) 0.3 (0.1)
BIS
Control 96 (5) 57 (6) 55 (7) 45 (5) 52 (9) 53 (6)
ACEI 96 (4) 55 (6) 53 (6) 47 (5) 54 (6) 52 (8)
ARA 97 (3) 57 (4) 53 (7) 44 (6) 55 (6) 52 (5)
ARA and ACEI during CPB
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Between termination of CPB and skin closure, there was
no difference in the number of patients requiring phenyleph-
rine administration, and in haemodynamic variables at T4
among the three groups. There were no differences in haem-
atocrit, rectal temperature, ET-Isof and BIS at each time
point of measurements among three groups (Table 4).
Discussion
In this study, the effects of long-term ARA and ACEI med-
ication on changes in vasoconstrictive neurohormonal levels
such as epinephrine, norepinephrine, AVP and angiotensin
II, haemodynamic variables and vasoconstrictor require-
ment during CPB were evaluated. The results demonstrated
that chronic ARA treatment resulted in a more profound
hypotension and a greater need for vasoconstrictor treatment
than ACEI treatment during CPB, and it may be associated
with direct blockade of angiotensin II receptor by ARA.
Sympathetic nervous system, AVP and RAS are the main
vasopressor systems for sustaining arterial blood pressure.13
Each system may act as a compensatory mechanism when-
ever the other system is depressed. Angiotensin II exerts its
effects through angiotensin II receptor subtype1 (AT1
receptor) and subtype2 (AT2 receptor).1 13 14 Most physio-
logical effects of angiotensin II, including vasoconstriction,
renal salt and water retention, aldosterone and AVP release,
and sympathetic facilitation, are mediated by the AT1
receptor. By contrast, AT2 receptor activation is associated
with antiproliferation, cell differentiation and development,
tissue degeneration and apoptosis. Theoretical advantage of
ARA over ACEI is that it is more specific to the RAS. ARA
selectively binds to AT1 receptor and acts independent of
angiotensin II synthesis pathway, allowing more complete
blockade of the RAS compared with ACEI. And, the com-
pensatory increase of angiotensin II by ARA may cause the
stimulation of the unblocked AT2 receptor, which could
exert beneficial effects in terms of vascular and cardiac
remodelling. In addition, ARA does neither elevate circu-
lating bradykinin level nor elicit coughing.15 In this study,
angiotensin II level significantly increased during CPB com-
pared with values before CPB in all three groups. This was
consistent with the previous studies reporting increased
plasma renin activity, aldosterone and angiotensin II con-
centrations during CPB as a result of CPB-induced RAS
activation.10 11 16 However, SVRI was significantly lower
in the ARA group when compared with that in the ACEI
group in spite of a greater amount of phenylephrine admin-
istered during CPB. In addition, the plasma angiotensin II
level was significantly higher in the ARA group than that in
the ACEI group during CPB. Therefore, these results sug-
gest that ARA might have blocked vasoconstrictive action
of angiotensin II on AT1 receptor during CPB, and caused
the compensatory increase in plasma angiotensin II level.
It is well known that preoperative RAS antagonist med-
ication blunts vasoactive response in anaesthetized patients
not only by inhibition of RAS but also by modulating other
vasoconstrictive neurohormones such as AVP. AVP as an
antidiuretic hormone, modulates vascular tone via V1a
receptors on vascular smooth muscle. In humans, AVP
release is stimulated by increase in the osmolality of the
extracellular fluid compartment, decrease in the circulating
blood volume, and a decrease in arterial blood pressure.17 18
Several other stimuli for AVP release have been identified,
including norepinephrine and angiotensin II. During CPB,
increase in AVP level to more than six times, often exceed-
ing 100 pg ml1 has been reported.9 19 In this study, AVP
level increased during CPB in all three groups, especially
about five times higher than before CPB value at 15 min
after the start of CPB. Among three groups, AVP level was
significantly lower in the ARA group than in the control
group before and 15 min after the start of CPB. This might
be associated with the direct blockade of the AT1 receptor,
which is one of the stimulators for AVP release. In the ACEI
group, although phenylephrine requirement during CPB
was not different compared with the control group, MAP
and SVRI were significantly lower than control group before
aortic unclamping. These results suggest that lower AVP
level in the ACEI group compared with the control group
during CPB seemed to be responsible, and were compatible
with a previous report of the association of AVP deficiency
with deleterious hypotension during CPB.12 However,
angiotensin II level was not different between the ACEI
and control group during the surgery. This may be attrib-
utable to generation of angiotensin II by other enzymes,
such as chymase, chymostatin-sensitive angiotensin II gen-
erating enzyme, tissue plasminogen activator.16 20 Licker
and colleagues11 also reported that there were no differences
in catecholamine and angiotensin II levels between the
ACEI and control group during cardiac surgery. Between
induction and before CPB, phenylephrine was used more
frequently in the ARA group than in other groups. Even
though neurohormonal levels were not measured at
anaesthetic induction time, similar changes in AVP and
angiotensin II level might have occurred at this time because
previous studies reported that there were no significant
changes of neurohormonal levels between during the
induction of anaesthesia and before the start of CPB.11 21
Catecholamines have been used as the first-line drug for
treating hypotension associated with CPB. Our findings that
phenylephrine administration was necessary in all patients
during CPB in spite of marked increase in catecholamine
levels indicate that sympathetic activation alone is not suf-
ficient to maintain adequate blood pressure during CPB, and
the activity of the AVP and RAS also play an important role
on haemodynamics. The RAS antagonists have been
increasingly used in patients with valvular heart disease
for the purpose of attenuating pulmonary hypertension and
pulmonary vascular remodelling.22 23 In this study, consid-
ering the result that MAP could be barely maintained above
60 mm Hg in the ARA group during CPB despite admin-
istration of phenylephrine in doses beyond the clinically
recommended upper limit,24 preoperative long-term ARA
Oh et al.
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medication would be a serious challenge to anaesthesio-
logists during cardiac surgery. There was a report that vaso-
dilatory shock during CPB in patients chronically treated
with ACEI was successfully treated with angiotensin II.25
However, our study showed that angiotensin II cannot be
considered as an option in treating hypotension associated
with long-term ARA medication during CPB. Therefore,
we recommend the use of AVP as a second-line drug for
treating hypotension. There were some reports that AVP has
been successfully used in the treatment of deleterious
vasodilatory shock associated with RAS antagonist during
CPB.12 26 Furthermore, discontinuing ARA medication
before the surgery should be considered in patients on
chronic ARA medication. Some investigators demonstrated
that stopping ARA or ACEI therapy before surgery does not
increase either hypertensive episodes or congestive heart
failure perioperatively,2 27 and also it decreases the risk of
post-induction hypotension.28 Yet further studies regarding
these matters are warranted.
The limitations of this study are as follows: first, we did
not include patients with left ventricular ejection fraction
<50% or in NYHA functional class 3 or 4 in this study.
Congestive heart failure itself is a risk factor of vasodilatory
shock and is associated with alterations in many vasocon-
strictive and vasodilatory neurohumoral factors.12 17 29
Therefore, our results should not be extended to patients
with congestive heart failure. Second, the authors had no
knowledge of the patients’ haemodynamic state before start-
ing on ARA or ACEI medication, and this cannot be
excluded as confounding factors. However, as the patient
characteristic data and preoperative haemodynamic vari-
ables in all patients enrolled in this study were not different,
the effects of these confounding factors should be minimal.
Third, the differences in haemodynamic changes among
three groups were elucidated by the changes in vasocon-
strictive neurohormones. As potent vasodilatory substances
such as complement, kinin–kallikrein, cytokine, bradykinin
and prostaglandin were also activated during CPB,7 8 the
effects of ARA or ACEI medication on vasodilatory sub-
stance activities could not be excluded and further study is
needed in this area.
In conclusion, chronic ARA medication resulted in more
profound hypotension and needed greater dose of vasocon-
strictor than ACEI medication during CPB, and it may be
associated with the blockade of vasoconstrictive action of
angiotensin II on AT1 receptor.
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